Meta-analysis of 18 RCTs of immune checkpoint inhibitor regimens: trial-level correlation between PFS and OS effects was moderate in gastro-oesophageal adenocarcinoma (R=0.82), strongest with PD-L1 CPS≥5 (R²=0.85), and weak in oesophageal squamous cell carcinoma (R=0.64).
Meta-analysisn = 18 trials
Leone et al. Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis